Streetbeat News

Analyst Ratings

ATVI

HPK

TTWO

VTLE

ZBH

Jim Cramer, host of CNBC's 'Mad Money Lightning Round', recommended buying Zimmer Biomet Holdings (ZBH) and Take-Two Interactive Software (TTWO), while expressing skepticism about Vital Energy (VTLE) and suggesting to sell Activision Blizzard (ATVI). He also showed support for HighPeak Energy (HPK), despite some hedge funds shorting it.

Portfolio Pulse from Lisa Levin

July 26, 2023 | 12:42 pm

TMHC

Wedbush analyst Jay McCanless has reiterated an Outperform rating on Taylor Morrison Home (NYSE:TMHC) and maintained a $61 price target.

Portfolio Pulse from richadhand@benzinga.com

July 26, 2023 | 12:41 pm

TPX

Wedbush analyst Seth Basham maintains an Outperform rating on Tempur Sealy Intl (NYSE:TPX) and raises the price target from $50 to $55.

Portfolio Pulse from richadhand@benzinga.com

July 26, 2023 | 12:40 pm

KPTI

Wedbush analyst David Nierengarten has maintained a Neutral rating on Karyopharm Therapeutics (NASDAQ:KPTI) and lowered the price target from $7 to $4.

Portfolio Pulse from richadhand@benzinga.com

July 26, 2023 | 12:39 pm

GOSS

Wedbush analyst Andreas Argyrides maintains an Outperform rating on Gossamer Bio (NASDAQ:GOSS) but lowers the price target from $7 to $5.

Portfolio Pulse from richadhand@benzinga.com

July 26, 2023 | 12:38 pm

BIIB

Wedbush analyst Laura Chico maintains a Neutral rating on Biogen (NASDAQ:BIIB) and lowers the price target from $269 to $268.

Portfolio Pulse from richadhand@benzinga.com

July 26, 2023 | 12:37 pm

PACW

Wedbush analyst David Chiaverini maintains a Neutral rating on PacWest Banc (NASDAQ:PACW) and raises the price target from $8 to $10.

Portfolio Pulse from richadhand@benzinga.com

July 26, 2023 | 12:36 pm

HAFC

Wedbush analyst David Chiaverini maintains a Neutral rating on Hanmi Financial (NASDAQ:HAFC) and raises the price target from $17 to $19.

Portfolio Pulse from richadhand@benzinga.com

July 26, 2023 | 12:35 pm

TERN

JMP Securities analyst Silvan Tuerkcan has reiterated a Market Outperform rating on Terns Pharma (NASDAQ:TERN) and maintained a $17 price target.

Portfolio Pulse from richadhand@benzinga.com

July 26, 2023 | 12:33 pm

RRC

Wells Fargo analyst Roger Read has maintained an Overweight rating on Range Resources (NYSE:RRC) and raised the price target from $33 to $35.

Portfolio Pulse from Benzinga Newsdesk

July 26, 2023 | 12:33 pm